Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Capital Expenditures (2016 - 2021)

BioCorRx (BICX) has disclosed Capital Expenditures for 7 consecutive years, with $2017.0 as the latest value for Q1 2021.

  • Quarterly Capital Expenditures changed N/A to $2017.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $2017.0 through Dec 2021, down 78.14% year-over-year, with the annual reading at $2017.0 for FY2021, 78.14% down from the prior year.
  • Capital Expenditures hit $2017.0 in Q1 2021 for BioCorRx, down from $2827.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6400.0 in Q3 2020 to a low of -$59326.0 in Q3 2018.
  • Historically, Capital Expenditures has averaged -$19073.2 across 4 years, with a median of -$984.0 in 2018.
  • Biggest five-year swings in Capital Expenditures: tumbled 5486.18% in 2019 and later soared 639900.0% in 2020.
  • Year by year, Capital Expenditures stood at -$984.0 in 2018, then crashed by 5486.18% to -$54968.0 in 2019, then skyrocketed by 105.14% to $2827.0 in 2020, then dropped by 28.65% to $2017.0 in 2021.
  • Business Quant data shows Capital Expenditures for BICX at $2017.0 in Q1 2021, $2827.0 in Q4 2020, and $6400.0 in Q3 2020.